Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker. Academic Article uri icon

abstract

  • INTRODUCTION: Plasma levels of amyloid-beta (A) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in A plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment; MCI) from normal controls. METHODS: 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2 hour time period. Changes in plasma A40 and42 levels were measured from either baseline or 5 minutes to the 10 minute time point. RESULTS: Compared to normal controls, subjects with AD/MCI had significantly less change () in plasma levels for both A40(-3.13(40.93)pg/ml vs. 41.34(57.16)pg/ml;p=0.002) and A42(-0.15(3.77)pg/ml vs. 5.64(10.65)pg/ml; p=0.004). DISCUSSION: OGTT combined with measures of plasma A40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

published proceedings

  • Alzheimers Dement (Amst)

altmetric score

  • 7

author list (cited authors)

  • Oh, E. S., Marano, C. M., Leoutsakos, J., Lee, R. W., Rissman, R. A., Smith, G. S., Craft, S., & Lyketsos, C. G.

citation count

  • 1

complete list of authors

  • Oh, Esther S||Marano, Christopher M||Leoutsakos, Jeannie-Marie||Lee, Rebecca W||Rissman, Robert A||Smith, Gwenn S||Craft, Suzanne||Lyketsos, Constantine G

publication date

  • September 2015

publisher